

## Contents

**Preface** *xv*

**Contributors** *xvii*

**Abbreviations** *xxi*

**Introduction: The Paradigm and Paradox of Liver Autoimmunity** *1*

*M. Eric Gershwin*

**Section I Scientific Basis of Clinical Autoimmune Liver Diseases** *3*

### **1 Introduction to the Physiology, Immunology and Pathology of the Liver and Biliary Tree** *5*

*Marco Carbone and Mario Strazzabosco*

Key Points *5*

Liver Cell Types and Organization *6*

Hepatic Metabolism *7*

Bilirubin Metabolism and Transport *7*

Carbohydrate Metabolism *7*

Lipid Metabolism *8*

Protein Metabolism *8*

Metabolic Zonation *8*

Hepatic Transport Systems *9*

Basolateral (Sinusoidal) Transporters *9*

Apical (Canalicular) Transporters *11*

Drug Metabolism *11*

Bile Formation, Secretion and the Enterohepatic Circulation *12*

Bile Acid Synthesis and Metabolism *13*

Enterohepatic Bile Acid Circulation *13*

Death and Regeneration of Hepatocytes *14*

Cell Death *14*

Liver Regeneration *15*

Cholangiocyte Reaction to Biliary Damage *16*

Protective Role of Biliary  $\text{HCO}_3^-$  Secretion *16*

Cholangiocytes and Immunity *16*

Biochemical Markers and Patterns of Hepatic Injury *17*

Hepatocellular Necrosis *18*

Cholestasis *18*

References *20*

## 2 Concepts of Autoimmunity Relevant to Autoimmune Liver Diseases 21

*Isaiah G. Roepe and John M. Vierling*

Key Points 21

Introduction 22

Role of Innate and Adaptive Immunity in Autoimmunity in the Context of the Liver as an Immune Organ 22

Overview 22

Innate Immunity 23

Liver as an Innate Immune Organ 25

Adaptive Immunity and Adaptive Immune Functions of the Liver 25

Role of the Liver as an Adaptive Immune Organ 28

Generation and Maintenance of Tolerance to Self-antigens 28

Overview 28

Central Tolerance 29

Central T-cell Tolerance 29

Central B-cell Tolerance 29

Peripheral Tolerance 30

T- and B-cell Clonal Anergy 30

T-cell Mediated Immune Regulation 30

Natural and Inducible T Regulatory Cells 30

Peripheral B-cell Regulatory Mechanisms 31

Regulatory Dendritic Cells 31

Immunoregulatory Interplay Between Treg and Th17 Cells 31

Risk Factors for Autoimmune Diseases 31

Genetics 31

Complex Genetic and Monogenic Diseases 31

HLA Risk Alleles 32

Non-HLA Gene Associations 32

Critical Role of Epigenetics 33

Transcription Factor Enhancers and Super Enhancers 33

MicroRNAs 33

Sex and Sex Hormones 33

Vitamin D and Sunlight Exposure 34

Loss of Immune Tolerance to Autoantigens and Perpetuation of Autoimmune Diseases 34

Overview 34

Role of the Microbiome 35

Mechanisms of Loss of Tolerance to Autoantigens 35

Bacterial and Viral Infections 35

Molecular Mimicry of Autoantigens 36

Neoantigens 36

Failure of Apoptosis to Conceal Autoantigens and Eliminate Autoreactive Cells 36

Immune Deviation of Activated T Cells 37

T-cell Receptor Revision in the Periphery 37

Perpetuation of Autoimmune Diseases 37

Epigenetics 37

Epitope Spreading 38

Tissue Memory T Cells 38

Cytokines Promoting Chronic Inflammation and Autoimmunity	38
Tertiary Lymphoid Structures and Germinal Centers	39
Epithelial Cell-induced Transformation of iTreg to Th17 Cells	39
Prevention of Autoimmunity and Therapeutic Control of Autoimmune Diseases	39
Overview	39
Strategies to Prevent Autoimmunity	39
Vitamin D <sub>3</sub>	39
Gut Microbiota Manipulation in Pregnancy and Infancy	39
Oral Tolerance	39
Strategies to Treat Established Autoimmune Diseases	40
Inducible T Regulatory T Cells	40
Epigenetic Enhancer Regulation	40
References	44

### 3 Genetics and Risk of Autoimmune Liver Diseases 47

<i>George F. Mells</i>	
Key Points	47
Introduction	48
HLA Associations in Autoimmune Liver Disease	50
Non-HLA Associations in Autoimmune Liver Disease	53
Conclusion	61
References	62

### 4 Autoantibodies and Understanding of Autoimmune Liver Diseases 65

<i>Benedetta Terziroli Beretta-Piccoli, Giorgia Mieli-Vergani, and Diego Vergani</i>	
Key Points	65
Introduction	66
Methods of Detection	66
Anti-nuclear Antibody	68
History	68
Immunofluorescence Reactivities and Antigenic Targets	68
Clinical Significance in Autoimmune Liver Disease	70
Anti-smooth Muscle and Anti-actin Antibodies	73
History	73
Immunofluorescence Reactivities, Antigenic Targets, and Clinical Significance	73
Anti-liver-kidney Microsomal Antibody	74
History	74
Immunofluorescence Reactivities, Antigenic Targets, and Clinical Significance	75
Anti-liver Cytosol Type 1 Antibody	76
History	76
Immunofluorescence Reactivities, Antigenic Targets, and Clinical Significance	76
Anti-soluble Liver Antigen Antibody	76
History	76
Immunofluorescence Reactivities, Antigenic Targets, and Clinical Significance	77
Anti-neutrophil Cytoplasmic Antibody	77
History	77
Immunofluorescence Reactivities, Antigenic Targets, and their Clinical Significance	77

Anti-mitochondrial Antibody	78
History	78
Immunofluorescence Reactivities, Antigenic Targets, and their Clinical Significance	78
Anti-asialoglycoprotein Receptor Antibody	79
History	79
Immunofluorescence Reactivities, Antigenic Targets, and their Clinical Significance	79
Indications for Autoimmune Liver Serology Testing	79
Concluding Remarks	81
References	82

## 5 Environmental Exposure and Risk in Autoimmune Liver Diseases 83

<i>Ying Qi Li and Andrew L. Mason</i>	
Key Points	83
Introduction	84
Autoimmunity	84
Interaction of Genes and Environmental Triggers in Autoimmunity	85
Mechanisms for Triggering Autoimmunity	86
Primary Biliary Cholangitis	89
Geo-epidemiology, Clusters, and Case–Control Studies of PBC	92
Bacterial Infection and PBC	93
Xenobiotics and PBC	96
Viruses in PBC	97
Autoimmune Hepatitis	99
Prospectus	101
References	102

## Section II Autoimmune Liver Diseases and Their Clinical Correlation 103

## 6 Autoimmune Hepatitis 105

<i>Aliya Gulamhusein and Patrick McKiernan</i>	
Key Points	105
Introduction	106
Definition and Pathophysiology	106
Epidemiology	107
Presentation	108
Adult-onset AIH	108
Pediatric-onset AIH	109
Diagnosis	109
Autoimmune Sclerosing Cholangitis	112
Treatment	112
Therapeutic Approach in Adults	113
First-line Therapy	113
Withdrawal of Therapy	114
Second-line Options	114
Therapeutic Approach in Children	115
First-line Therapy	115
Withdrawal of Therapy	115

Second-line Options	115
Prognosis	116
Adulthood	116
Childhood	116
References	118

## 7 Primary Biliary Cholangitis 123

*Alessio Gerussi and Marco Carbone*

Key Points	123
Introduction and Definition	124
Epidemiology	124
Etiopathogenesis	125
Clinical Presentation	126
Asymptomatic Patients	126
Symptomatic Patients	126
Diagnosis	127
Biochemical Tests	127
Autoantibodies	128
Liver Biopsy	128
Imaging	130
Differential Diagnosis	130
Natural History	130
Disease Course in the UDCA Era	131
Risk Stratification	132
Treatment	134
Ursodeoxycholic Acid	134
Obeticholic Acid	135
Fibric Acid Derivatives	136
Budesonide	137
Liver Transplantation	137
Symptom Management	137
Complications of Liver Disease	139
Osteoporosis	139
Advanced Liver Disease	140
Varices	140
HCC	140
Useful Websites	141
References	141

## 8 Primary Sclerosing Cholangitis 143

*Mette Vesterhus, Benedetta Terziroli Beretta-Piccoli, Kirsten Muri Boberg, and Giorgina Mieli-Vergani*

Key Points	143
Introduction	144
Definition	145
Adult PSC	145
Epidemiology	145
Diagnosis	146
Diagnosis of Variant Phenotypes	147
Presentation	147

Malignancy	149
Cholangiocarcinoma	149
Gallbladder Cancer	150
Colorectal Cancer	150
Prognosis	150
Risk Stratification: Clinical Characteristics	150
Natural History Models	151
ALP and Bilirubin	151
Non-invasive Evaluation of Fibrosis	151
Treatment	152
Medical Treatment	152
Bile Acid Therapy	153
Microbiota Modulators	153
Anti-inflammatory Treatment	154
Antibiotic Therapy	154
Endoscopic Treatment	154
Surveillance for Malignancy	154
Colorectal Cancer: Colonoscopy	155
Gallbladder Cancer: Ultrasound	155
Hepatocellular Cancer: Ultrasound	155
Cholangiocarcinoma	155
Bone Mineral Density	155
Juvenile Sclerosing Cholangitis	155
Epidemiology in Pediatric Disease	155
Autoimmune Sclerosing Cholangitis	156
Diagnosis in Children	156
Clinical Features in Pediatric Disease	158
Treatment of Pediatric Disease (ASC and Juvenile PSC)	158
Prognosis in Pediatric Disease	159
Conclusion	159
References	160
<b>9 IgG4-Related Liver and Biliary Disease</b>	<b>163</b>
<i>Eleanor Barnes and Emma L. Culver</i>	
Key Points	163
Introduction and Historical Perspective	164
Etiology and Pathogenesis of IgG4-RD	165
Development and Characteristics of an IgG4 Antibody Response	165
Antigens That May Drive an IgG4-RD Response	166
IgG4 Antibodies and Pathogenesis	167
Incidence and Prevalence of IgG4-RD	167
Clinical Characteristics of IgG4-related Hepatobiliary Disease	168
Hepatobiliary Disease	168
Disease Outside the Hepatobiliary System	168
Diagnostic Criteria, Histologic Features, and Approach to Diagnosis of IgG4-related Hepatobiliary Disease	168
Diagnostic Criteria for AIP and IgG4-RD	168
Histologic Diagnosis of IgG4-related Hepatobiliary Disease	170

Utility of Blood Tests, Including Serum IgG4 Levels in IgG4-RD Diagnostics	171
Common Alternative Diagnoses to Consider	172
Radiologic Characteristics of Hepatobiliary IgG4-RD	173
IgG4-RD and Relationship with Malignancy	173
Management and Treatment of Patients with IgG4-RD	174
Monitoring and Follow-up	175
Conclusions and Future Directions	175
References	177

### Section III Specific Clinical Challenges 181

#### 10 Managing Acute and Chronic Seronegative Liver Disease 183

*Marcus C. Robertson and Peter C. Hayes*

Key Points 183

Introduction 184

An Approach to Seronegative Acute Liver Failure 184

Potential Causes of Seronegative ALF and Features that Suggest  
an Autoimmune Pathogenesis 185

Clinical Features of Seronegative ALF 188

Risk Stratification in Seronegative ALF 188

Management of Seronegative ALF 189

*N*-Acetylcysteine 190

Corticosteroids 190

Emergency Liver Transplantation 191

An Approach to Cryptogenic Chronic Liver Disease 192

Potential Causes of Seronegative Chronic Liver Disease and Features that  
Suggest an Autoimmune Pathogenesis 192

Non-alcoholic Fatty Liver Disease 194

Wilson Disease 194

Seronegative Autoimmune Hepatitis 195

Seronegative Primary Biliary Cholangitis 197

Conclusion 197

References 198

#### 11 Managing Pregnant Women with Autoimmune Liver Disease 201

*Eleni Theodoridou and Michael A. Heneghan*

Key Points 201

Introduction 202

Fertility in AIH 202

Pregnancy Outcomes in AIH 202

Liver-related Outcomes in Pregnancy 206

Pregnancy in Cirrhosis 209

Safety of Medication in Pregnancy 210

Summary 213

References 214

## 12 Bone Health in Patients with Autoimmune Liver Diseases 219

*Albert Parés and Núria Guañabens*

Key Points 219

Introduction 220

Prevalence of Osteoporosis and Fractures 222

Primary Biliary Cholangitis 222

Primary Sclerosing Cholangitis 223

Autoimmune Hepatitis 223

Pathogenesis 224

Assessment of Bone Disease 226

Prevention and Treatment of Bone Loss 227

General Measures 227

Pharmacologic Agents 227

Bisphosphonates 227

Other Agents 229

Summary 230

References 231

## Section IV Transplantation and Its Role in Autoimmune Liver Disease 233

## 13 Recurrent Autoimmune Liver Disease and Its Impact on Clinical Practice 235

*Carlos Moctezuma-Velázquez and Aldo J. Montano-Loza*

Key Points 235

Introduction 236

Primary Biliary Cholangitis 236

Recurrence of PBC After LT 236

Diagnosis of PBC After LT 236

Risk Factors Associated with PBC Recurrence After LT 237

Treatment of PBC Recurrence After LT 238

Prognostic Impact of PBC Recurrence After LT 239

Primary Sclerosing Cholangitis 239

Recurrence of PSC After LT 240

Diagnosis of Recurrence of PSC After LT 240

Risk Factors Associated with PSC Recurrence After LT 240

Treatment of PSC Recurrence After LT 241

Prognostic Impact of PSC Recurrence After LT 241

Autoimmune Hepatitis 241

Recurrence of AIH After LT 242

Risk Factors Associated with AIH Recurrence After LT 242

Treatment of AIH Recurrence After LT 243

Prognostic Impact of AIH Recurrence After LT 243

Conclusions 243

References 244

## 14 Recurrent Autoimmune Liver Disease and its Scientific Significance 247

*Atsushi Tanaka, Patrick S.C. Leung, and M. Eric Gershwin*

Key Points 247

Introduction 247

Recurrence of PBC 248

Incidence and Diagnosis of Recurrent PBC 249



Risk Factors of Recurrent PBC	250
Impact of Recurrent PBC on Long-term Outcomes	250
Recurrence of PSC	251
Incidence and Diagnosis of Recurrent PSC	252
Risk Factors of Recurrent PSC	253
Impact of Recurrent PSC on Long-term Outcomes	254
Recurrence of AIH	254
Incidence and Diagnosis of Recurrent AIH	254
Risk Factors of Recurrent AIH	255
Impact of Recurrent AIH on Long-term Outcomes	255
Concluding Remarks	256
References	257

## Section V Controversies in Autoimmune Liver Diseases 263

### 15 Making Sense of Overlap and Crossover Syndromes 265

*Olivier Chazouillères*

Key Points	265
Introduction	266
General Considerations	267
Liver Biopsy	268
AIH Scores	269
Genetics	269
PBC/AIH Overlap Syndrome	269
PSC/AIH Overlap Syndrome	272
Liver Transplantation	273
Conclusions	274
References	275

### 16 The Role of Extrahepatic Autoimmunity in Autoimmune Liver Disease 277

*Ewa Wunsch and Piotr Milkiewicz*

Key Points	277
Introduction	278
Epidemiology	278
Autoimmune Thyroid Disease	279
Sjögren Syndrome	279
Systemic Sclerosis	280
Systemic Lupus Erythematosus	281
Rheumatoid Arthritis	282
Celiac Disease	283
Inflammatory Bowel Disease	284
Conclusions	286
Guidelines for Clinicians	287
References	288

### 17 Symptoms, Chronic Disease, and Patient Management 289

*David Jones*

Key Points	289
Background	290
Goals of Treatment	290

- Symptoms, Quality of Life, and Health Utility: Key Concepts 291
  - Symptoms 291
  - Health-related Quality of Life 292
  - Health Utility 292
- Symptoms and Their Management in AILD 292
  - Impact of Disease-modifying Therapy on Symptoms in AILD 292
  - Stage-associated Symptoms 293
  - Stage-independent Symptoms 293
    - Pruritus 293
    - Fatigue and Cognitive Symptoms 295
    - Social Isolation Symptoms 298
- Effective Care Delivery in AILD 299
- References 300

Index 301